236 related articles for article (PubMed ID: 28119394)
21. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.
Dzimitrowicz H; Berger M; Vargo C; Hood A; Abdelghany O; Raghavendra AS; Tripathy D; Valero V; Hatzis C; Pusztai L; Murthy R
J Clin Oncol; 2016 Oct; 34(29):3511-3517. PubMed ID: 27298406
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy.
Dhillon S
Drugs; 2014 Apr; 74(6):675-86. PubMed ID: 24659374
[TBL] [Abstract][Full Text] [Related]
23. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
24. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.
Lynce F; Barac A; Geng X; Dang C; Yu AF; Smith KL; Gallagher C; Pohlmann PR; Nunes R; Herbolsheimer P; Warren R; Srichai MB; Hofmeyer M; Cunningham A; Timothee P; Asch FM; Shajahan-Haq A; Tan MT; Isaacs C; Swain SM
Breast Cancer Res Treat; 2019 Jun; 175(3):595-603. PubMed ID: 30852761
[TBL] [Abstract][Full Text] [Related]
25. Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?
Ricci F; Le Tourneau C
Chin Clin Oncol; 2018 Feb; 7(1):3. PubMed ID: 29156892
[No Abstract] [Full Text] [Related]
26. Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?
Fabi A; Giannarelli D; Moscetti L; Santini D; Zambelli A; Laurentiis M; Caruso M; Generali D; Valle E; Leonardi V; Cannita K; Arpino G; Filippelli G; Ferretti G; Giampaglia M; Montemurro F; Nisticò C; Gasparro S; Cognetti F
Future Oncol; 2017 Dec; 13(30):2791-2797. PubMed ID: 29182361
[TBL] [Abstract][Full Text] [Related]
27. HER2-positive breast cancer: Current and new therapeutic strategies.
Escrivá-de-Romaní S; Arumí M; Bellet M; Saura C
Breast; 2018 Jun; 39():80-88. PubMed ID: 29631097
[TBL] [Abstract][Full Text] [Related]
28. Optimal treatment of early stage HER2-positive breast cancer.
Pernas S; Barroso-Sousa R; Tolaney SM
Cancer; 2018 Dec; 124(23):4455-4466. PubMed ID: 30291791
[TBL] [Abstract][Full Text] [Related]
29. [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers].
Guerin M; Sabatier R; Gonçalves A
Bull Cancer; 2015 Apr; 102(4):390-7. PubMed ID: 25790739
[TBL] [Abstract][Full Text] [Related]
30. The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.
Diéras V; Bachelot T
Target Oncol; 2014 Jun; 9(2):111-22. PubMed ID: 23852665
[TBL] [Abstract][Full Text] [Related]
31. Trastuzumab emtansine for HER2-positive advanced breast cancer.
Verma S; Miles D; Gianni L; Krop IE; Welslau M; Baselga J; Pegram M; Oh DY; Diéras V; Guardino E; Fang L; Lu MW; Olsen S; Blackwell K;
N Engl J Med; 2012 Nov; 367(19):1783-91. PubMed ID: 23020162
[TBL] [Abstract][Full Text] [Related]
32. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
Krop IE; Lin NU; Blackwell K; Guardino E; Huober J; Lu M; Miles D; Samant M; Welslau M; Diéras V
Ann Oncol; 2015 Jan; 26(1):113-119. PubMed ID: 25355722
[TBL] [Abstract][Full Text] [Related]
33. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Tesch ME; Gelmon KA
Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
[TBL] [Abstract][Full Text] [Related]
34. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686
[TBL] [Abstract][Full Text] [Related]
35. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
[TBL] [Abstract][Full Text] [Related]
36. HER2 aberrations in cancer: implications for therapy.
Yan M; Parker BA; Schwab R; Kurzrock R
Cancer Treat Rev; 2014 Jul; 40(6):770-80. PubMed ID: 24656976
[TBL] [Abstract][Full Text] [Related]
37. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Li BT; Shen R; Buonocore D; Olah ZT; Ni A; Ginsberg MS; Ulaner GA; Offin M; Feldman D; Hembrough T; Cecchi F; Schwartz S; Pavlakis N; Clarke S; Won HH; Brzostowski EB; Riely GJ; Solit DB; Hyman DM; Drilon A; Rudin CM; Berger MF; Baselga J; Scaltriti M; Arcila ME; Kris MG
J Clin Oncol; 2018 Aug; 36(24):2532-2537. PubMed ID: 29989854
[TBL] [Abstract][Full Text] [Related]
38. Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer.
Watanabe J; Ito Y; Saeki T; Masuda N; Takano T; Takao S; Nakagami K; Tsugawa K; Nakagawa S; Kanatani K; Nakayama T
In Vivo; 2017; 31(3):493-500. PubMed ID: 28438884
[TBL] [Abstract][Full Text] [Related]
39. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
[TBL] [Abstract][Full Text] [Related]
40. Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer.
Patel KC; Hageman K; Cooper MR
Am J Health Syst Pharm; 2014 Apr; 71(7):537-48. PubMed ID: 24644113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]